Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Open-Label Study of Anhydrous Enol-Oxaloacetate in Subjects With Newly Diagnosed Glioblastoma Multiforme

Next Previous
Trial Profile

A Phase 2, Randomized, Open-Label Study of Anhydrous Enol-Oxaloacetate in Subjects With Newly Diagnosed Glioblastoma Multiforme

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enol oxaloacetate (Primary) ; Antiepileptic drugs; Temozolomide
  • Indications Glioblastoma
  • Focus Proof of concept; Therapeutic Use
  • Sponsors MetVital

Most Recent Events

  • 25 Jun 2020 Status changed from planning to not yet recruiting.
  • 18 Jun 2019 New trial record
  • 11 Jun 2019 According to a MetVital, Inc media release, the U.S. Food and Drug Administration (FDA) has notified MetVital that it may proceed with its clinical investigation of Anhydrous Enol-Oxaloacetate (AEO) as a potential treatment for patients with Glioblastoma Multiforme. The notice to proceed was received following MetVital's submission of an investigational new drug (IND) application for this program. FDA has approved a Phase 2A Proof of Concept trial to advance.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top